RCMI Coordinating Center (RCMI CC) Header Logo

Connection

John S. Cooperwood to Cell Line, Tumor

This is a "connection" page, showing publications John S. Cooperwood has written about Cell Line, Tumor.
Connection Strength

0.207
  1. Musa MA, Joseph MY, Latinwo LM, Badisa V, Cooperwood JS. In vitro evaluation of 3-arylcoumarin derivatives in A549 cell line. Anticancer Res. 2015 Feb; 35(2):653-9.
    View in: PubMed
    Score: 0.082
  2. Wan Z, Musa MA, Joseph P, Cooperwood JS. Synthesis and biological activity of 3-N-substituted estrogen derivatives as breast cancer agents. Mini Rev Med Chem. 2013 Jul; 13(9):1381-8.
    View in: PubMed
    Score: 0.074
  3. Green JE, Cooperwood JS, Taka E, Soliman KF, Goodman CB, Reams RR. Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics. 2014 Jul-Aug; 11(4):195-200.
    View in: PubMed
    Score: 0.020
  4. Musa MA, Badisa VL, Latinwo LM, Cooperwood J, Sinclair A, Abdullah A. Cytotoxic activity of new acetoxycoumarin derivatives in cancer cell lines. Anticancer Res. 2011 Jun; 31(6):2017-22.
    View in: PubMed
    Score: 0.016
  5. Musa MA, Cooperwood JS, Khan MO, Rahman T. In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs. Arch Pharm (Weinheim). 2011 Feb; 344(2):102-10.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support